Skip to main content

Table 5 Univariate analysis of prognostic factors for patients with locoregionally advanced NPC

From: Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study

Variate

5-year survival rate (%)

OS

P

LRRFS

P

DMFS

P

DFS

P

Gender

 

0.173

 

0.587

 

0.077

 

0.224

 Male

75.8

 

87.1

 

75.3

 

65.9

 

 Female

88.0

 

83.3

 

85.8

 

74.0

 

Age (years)

 

0.002

 

0.489

 

0.025

 

0.007

 <50

82.8

 

87.0

 

81.5

 

73.1

 

 ≥50

68.6

 

84.6

 

68.4

 

55.6

 

WHO histology

 

0.362

 

0.564

 

0.526

 

0.549

 Type II

87.1

 

90.3

 

83.3

 

74.5

 

 Type III

77.5

 

85.8

 

76.9

 

66.9

 

T stage

 

0.213

 

0.070

 

0.773

 

0.299

 T1–2

84.4

 

96.4

 

81.3

 

78.1

 

 T3–4

77.4

 

84.6

 

76.9

 

66.0

 

N stage

 

0.934

 

0.475

 

0.414

 

0.994

 N0–1

80.8

 

85.2

 

79.4

 

67.2

 

 N2–3

75.1

 

87.8

 

74.9

 

68.2

 

Overall stage

 

<0.001

 

0.518

 

0.001

 

0.004

 III

85.6

 

87.7

 

84.9

 

74.7

 

 IV

66.5

 

83.5

 

65.3

 

56.2

 

Treatment

 

0.599

 

0.515

 

0.456

 

0.517

 NAC + IMRT

78.0

 

87.9

 

79.0

 

69.8

 

 CCRT + AC

78.7

 

84.8

 

76.2

 

65.6